Video

Study finds UGN-102 well-tolerated in patients with NMIBC

Author(s):

Urology Times staff

In this video, William C. Huang, MD, discusses the findings and takeaways of a recent phase 2b trial published in the Journal of Urology, which investigates the agent UGN-102 as a treatment for patients with non–muscle-invasive bladder cancer (NMIBC). Huang is a professor in the departments of urology and radiology at the New York University Grossman School of Medicine and the chief of urology at Tisch Hospital, New York City.

Related Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content
Neoadjuvant APL-1202 plus tislelizumab is safe in patients with MIBC
February 24th 2025

Neoadjuvant APL-1202 plus tislelizumab is safe in patients with MIBC

Hannah Clarke
The pCR rate was 33% with APL-1202 plus tislelizumab compared with 26% with tislelizumab alone.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
February 18th 2025

RETAIN-2 interim data promising for dose-dense MVAC plus nivolumab in MIBC

Benjamin P. Saylor
“Among active surveillance patients, 82% are metastases-free, and 60% were metastases-free and had an intact, unradiated bladder,” said Pooja Ghatalia, MD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021

Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

Urology Times staff
“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Urinary bladder cancer | Image Credit: © Matthieu - stock.adobe.com
February 16th 2025

Disitamab vedotin plus toripalimab shows safety, efficacy in MIBC

Benjamin P. Saylor
"The results [indicate] that neoadjuvant DV combined with toripalimab had promising efficacy and acceptable safety in patients with HER2-expressing MIBC,” said Xinan Sheng, MD.
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
February 15th 2025

Additional NIAGARA data spotlight benefits of durvalumab plus chemo for MIBC

Benjamin P. Saylor
The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.
© 2025 MJH Life Sciences

All rights reserved.